Vfend Use In Febrile Neutropenia Should Be Limited To High-Risk Patients
Executive Summary
Pfizer's Vfend indication for empirical antifungal therapy in febrile neutropenia could be limited to high-risk patients, the Antiviral Drugs Advisory Committee suggested to FDA in an Oct. 4 meeting.
You may also be interested in...
Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002